Measurable residual disease (MRD) below 0.01%, adequate CD34+ cell infusion, chronic GVHD, or cytomegalovirus reactivation may provide protective effects against relapses in pediatric HSCT recipients with T-ALL (17). The gene discussed is CD34; the disease is acute lymphoblastic leukemia.